Altevax Biotech

📍 Paris, France🗓 Founded 2016👥 6 employees💰 Last funded Jun 2020
Pharmaceutical Manufacturing🌐 altevax.com
Website LinkedIn
Altevax is developing a powerful pioneering immunotherapy technology against cancer. Its patented melanin-based technology has been proven in pre-clinical trials to boost an antigen-specific immune response with Cytotoxic T-lymphocytes (CD8+ Killer T cells), the body’s most powerful defenders. The Altevax immunotherapy technology works with a wide range of peptides. The Altevax technology is complementary to other anti-cancer immune technologies, such as anti PD1s. Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2024. Altevaxs partnership with Assistance Publique Hôpitaux de Paris and other research institutions enables it to leverage their resources and accelerate clinical trials.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Altevax Biotech?
Altevax Biotech has 1 investors on record on gritt.io, 1 mid-stage.
When did Altevax Biotech last raise funding?
The most recent investment in Altevax Biotech recorded on gritt.io was in June 2020.
When was Altevax Biotech founded?
Altevax Biotech was founded in 2016.
What industry is Altevax Biotech in?
Altevax Biotech operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Altevax Biotech based?
Altevax Biotech is headquartered in Paris, France.